Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name KMT2A rearrange
Gene Variant Detail

KMT2A rearrange (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06852222 Phase III Azacitidine + Bleximenib + Venetoclax Azacitidine + Venetoclax A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (cAMeLot-2) Recruiting USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS 6
NCT05886049 Phase I Cytarabine + Daunorubicin + Revumenib Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Recruiting USA 0
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting USA 0
NCT06930352 Phase II Ziftomenib Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Not yet recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT06652438 Phase III Revumenib Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Recruiting NLD | GBR | DEU 0
NCT07007312 Phase III Cytarabine + Daunorubicin Azacitidine + Venetoclax Cytarabine + Daunorubicin + Ziftomenib Azacitidine + Venetoclax + Ziftomenib Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Recruiting USA 0
NCT07053059 Phase II Obecabtagene autoleucel Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) Recruiting USA 0
NCT05748171 Phase II Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Recruiting SWE | SVK | POL | NOR | NLD | ITA | ISR | HUN | FRA | FIN | ESP | DNK | DEU | CZE | CHE | BEL | AUT 0
NCT02828358 Phase II Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Completed USA | CAN | AUS 1
NCT06397027 Phase I Azacitidine + Venetoclax + Ziftomenib A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias Recruiting USA 0
NCT06284486 Phase II Revumenib + Venetoclax A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib Recruiting USA 0
NCT05918692 Phase I BMF-500 A Phase 1 Study of BMF-500 in Adults With Acute Leukemia Active, not recruiting USA 0
NCT04067336 Phase Ib/II Itraconazole + Ziftomenib Ziftomenib Midazolam + Ziftomenib First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL 0
NCT03724084 Phase Ib/II Cytarabine + Daunorubicin + Pinometostat Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Terminated USA 0
NCT07059975 Phase I Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Idarubicin + Venetoclax Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide Cytarabine + Hydrocortisone + Methotrexate UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Recruiting USA 0
NCT06440135 Phase I Ziftomenib Ziftomenib Maintenance Post Allo-HCT Recruiting USA 0
NCT04811560 Phase Ib/II Bleximenib A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) (cAMeLot-1) Recruiting USA | ISR | GBR | FRA | ESP | CAN | BRA | AUS 4
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed USA 0
NCT03513484 Phase I Azacitidine + Nintedanib Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03114865 Phase Ib/II Blinatumomab + Dexamethasone A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Active, not recruiting USA 0
NCT05554393 Phase II Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Recruiting USA | CAN 1
NCT06376162 Phase I Cytarabine + Fludarabine + Ziftomenib Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia Recruiting USA | NLD | ITA | FRA | ESP | CAN | AUT 0
NCT06222580 Phase I Gilteritinib + Revumenib SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Recruiting USA 0
NCT05761171 Phase II Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Active, not recruiting USA | CAN 0
NCT04065399 Phase Ib/II Revumenib A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Recruiting USA | NLD | LTU | ITA | ISR | FRA | ESP | DEU | CAN | AUS 1
NCT05327894 Phase III Blinatumomab Interfant-21 Treatment Protocol for Infants Under 1 Year with KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21) Active, not recruiting SWE | SVK | NOR | NLD | LTU | ITA | IRL | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG 3
NCT06313437 Phase I Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib Revumenib in Combination With 7+3 + Midostaurin in AML Recruiting USA 0
NCT05326516 Phase I Revumenib A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Completed USA | CAN 0
NCT04307576 Phase III Imatinib Blinatumomab Inotuzumab ozogamicin A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting SWE | NOR | NLD | LTU | ISL | IRL | GBR | FRA | FIN | EST | DNK | DEU | BEL 1
NCT07052994 Phase I Cytarabine + Doxorubicin + Gemtuzumab ozogamicin + Revumenib A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients Not yet recruiting USA 0
NCT06177067 Phase I Cytarabine + Hydrocortisone + Methotrexate Azacitidine + Revumenib + Venetoclax Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Recruiting USA 0
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Active, not recruiting USA 0
NCT07155226 Phase Ib/II AZD3632 + Posaconazole AZD3632 Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (MOMENTUM) Not yet recruiting USA | ITA | GBR | DNK | DEU | CAN | AUS 2
NCT05735184 Phase I Cytarabine + Daunorubicin + Quizartinib + Ziftomenib Azacitidine + Venetoclax + Ziftomenib Cytarabine + Daunorubicin + Ziftomenib Venetoclax + Ziftomenib A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Recruiting USA 0
NCT06448013 Phase I Gemtuzumab ozogamicin + Venetoclax + Ziftomenib A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT05918913 Expanded access Revumenib Expanded Access Program for SNDX-5613 No longer available USA 0
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed USA | CAN 0
NCT06769490 Phase I Quizartinib + Ziftomenib Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia Recruiting USA 0
NCT02419755 Phase II Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated USA 0
NCT06575296 Phase I Revumenib Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant Recruiting USA 0
NCT06152809 Phase I Aldesleukin + CIML-NK cells + Venetoclax CIML NK Cells With Venetoclax for AML Recruiting USA 0
NCT04326439 Phase II Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone AflacLL1901 (CHOA-AML) Terminated USA 0
NCT05848687 Phase Ib/II Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II Recruiting USA | CAN 0
NCT04752163 Phase Ib/II Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Terminated USA 0
NCT06287229 Phase Ib/II Brexucabtagene autoleucel Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Vincristine Sulfate Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Recruiting USA 0
NCT06229912 Phase II Revumenib A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes Recruiting USA 0
NCT05507827 Phase I CD19-22.BB.z CAR T cells Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL Active, not recruiting USA 0
NCT04659616 Phase I Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT06173518 Phase I Obecabtagene autoleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting USA | GBR | ESP 0
NCT06001788 Phase I Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting USA | ITA | ESP 0
NCT07177079 Phase I Decitabine + Venetoclax Azacitidine + Venetoclax Azacitidine + Venetoclax + Vitamin C Decitabine + Venetoclax + Vitamin C High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) Not yet recruiting USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT06226571 Phase I Cytarabine + Idarubicin + Revumenib Revumenib Cytarabine + Daunorubicin + Revumenib Cytarabine A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Recruiting USA | NLD | GBR | ESP | CAN | AUS 0